Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.51 |
| ▸ | CTSK | P43235 | 4/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.51 |
| ▸ | TACR1 | P25103 | 2/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL269301 | 1.00 | CTSS (0.51) | CTSSCTSKSCN9ATACR1KLK5 | |
| SCHEMBL31494602 | 0.90 | CTSS (0.51) | CTSSCTSKSCN9ATACR1KLK5 | |
| SCHEMBL30825582 | 0.89 | TACR1 (0.49) | CTSSCTSKSCN9ATACR1KLK5 | |
| SCHEMBL31703417 | 0.89 | CTSS (0.50) | CTSSCTSKSCN9ATACR1KLK5 | |
| SCHEMBL268952 | 0.89 | PTPN1 (0.55) | CTSSCTSKSCN9APTPN1ACE | |
| SCHEMBL1509242 | 0.89 | PTPN1 (0.55) | CTSSCTSKSCN9APTPN1ACE | |
| SCHEMBL268951 | 0.89 | PTPN1 (0.55) | CTSSCTSKSCN9APTPN1ACE | |
| SCHEMBL1857532 | 0.88 | CTSS (0.49) | CTSSCTSKSCN9ATACR1KLK5 | |
| SCHEMBL30825581 | 0.88 | TACR1 (0.48) | CTSSCTSKSCN9ATACR1KLK5 | |
| SCHEMBL10249595 | 0.86 | TACR1 (0.45) | CTSSCTSKSCN9ATACR1KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910317-B1 | 1-AMINO LINKED COMPOUNDS | LILLY CO ELI (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-1910274-B1 | PHENYL COMPOUNDS | LILLY CO ELI (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8133907-B2 | Type II diabetes, obesity, hyperglycemia and a lipid disorder selected from dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL; additionally comprising metformin | ELI LILLY AND COMPANY (US) | 2012-03-13 | — | — | US | disclosed |
| US-8106090-B2 | Antidiabetic agents; prevent of non-insulin dependent diabetes | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-8076514-B2 | Dipeptidyl peptidase IV inhibitors; Type II diabetes; 2-[(2S,3R)-3-Amino-2-hydroxy-4-(2,4,5-trifluoro-phenyl)-butyl]-N-tert-butyl-4-chloro-benzamide Hydrochloride | ELI LILLY AND COMPANY (US) | 2011-12-13 | — | — | US | disclosed |
| EP-1912946-B1 | PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS | LILLY CO ELI (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080221217-A1 | Phenyl Compounds and Their Use in the Treatment of Type II Diabetes | ELI LILLY AND COMPANY | 2008-09-11 | — | — | US | disclosed |
| US-20080214616-A1 | Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors | ELI LILLY AND COMPANY | 2008-09-04 | — | — | US | disclosed |
| US-20080207735-A1 | 1-Amino Linked Compounds | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| EP-1912946-A1 | PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS | Eli Lilly and Company (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1910274-A1 | PHENYL COMPOUNDS | Eli Lilly and Company (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007015767-A1 | PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015807-A1 | PHENYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221217-A1 | Phenyl Compounds and Their Use in the Treatment of Type II Diabetes | DPP4, GPR119, SLC5A2 | CTSS 2054/4885CTSK 2871/4885SCN9A 990/4885 |
| US-20080207735-A1 | 1-Amino Linked Compounds | DPP4, DPP3, DPP9 | CTSS 1095/4885CTSK 2012/4885SCN9A 467/4885 |
| US-20080214616-A1 | Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors | DPP4, DPP3, DPP7 | CTSS 1680/4885CTSK 2589/4885SCN9A 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.